Show notes

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast. The Points of CARE, the official podcast of Diabetes, Obesity, and Cardiometabolic CARE, will highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. In this special inaugural episode, host Richard Beaser, MD also discusses the ADA's Obesity Association and the "Standards of Care in Overweight and Obesity."

4:15 Beaser speaks with Alissa Segal, PharmD, RPh, CDCES, CDTC, FCCP. Dr. Segal is editor in chief of Diabetes, Obesity, and Cardiometabolic CARE and professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences. Her editorial, "Diabetes, Obesity, and Cardiometabolic CARE: Building New From a Strong Foundation," is available for free at doi.org/10.2337/doci25-0010.

13:00 Samar Hafida, MBCCh, joins the conversation. Dr. Hafida is a board-certified endocrinologist and weight management specialist at Boston Medical Center and assistant professor of medicine (Endocrinology, Diabetes, Nutrition & Weight Management) at the Boston University Chobanian & Avedisian School of Medicine. She is also vice president of the ADA's Obesity Association. Her editorial, "Introducing the Obesity Association and the Launch of Our Official Journal," is available for free at doi.org/10.2337/doci25-0012.

17:55 Dr. Hafida discusses "Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity." This article is available for free at doi.org/10.2337/doci25-0008.

20:05 Richard and Alissa highlight a few articles from the first issue of Diabetes, Obesity, and Cardiometabolic CARE.

• Simpkins et al. "Association of Type 2 Diabetes Subgroups With Incident Peripheral Neuropathy" doi.org/10.2337/doc25-0051

• Livingston et al. "The Benefits and Costs of Treating Obesity Among Adults in the Medicaid Program" doi.org/10.2337/doci25-0005.

• Davidson et al. "Effectiveness of Using Patient-Defined Meal Sizes to Determine Bolus Doses of Insulin" doi.org/10.2337/doc25-0018

• Ali et al. "Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity" doi.org/10.2337/doc25-0026

• Masiano et al. "Type 2 Diabetes Treatment and Experience With Hospitalization in Older Adults: A Convergent Mixed-Methods Study" doi.org/10.2337/doc25-0009

• Young et al. "The Critical Role of Diabetology Pharmacists in Improving Cardiovascular-Kidney-Metabolic Care and Outcome" doi.org/10.2337/doc25-0049

To learn more about Diabetes, Obesity, and Cardiometabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss diagnosis and treatment of MASH using a case-based approach with two master clinicians, one a hepatologist and the other a primary care physician. This special episode is supported by an independent educational grant from Boehringer Ingelheim.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Alina M. Allen, M.D. Associate Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where she serves as the Director of Hepatology and Director of the MASLD Clinic.

Susan Kuchera, M.D. - Program Director of the Jefferson Health Abington Family Medicine Residency Program, Clinical Associate Professor of Family and Community Medicine in the Sidney Kimmel Medical College of Thomas Jefferson University

Selected references:

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082

In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is sponsored with support from Novo Nordisk.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

W. Timothy Garvey, MD., Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham.

Selected references:

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton Sean et al. N Engl J Med 2025;393:1077-1087

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff, A Michael, et al. N Engl J Med 2023;389:2221-2232